Thromb Haemost 2002; 87(01): 170
DOI: 10.1055/s-0037-1612962
Letters to the Editor
Schattauer GmbH

Absence of Mutations at the APC Interacting Sites of Factor VIII in Caucasians

Jens Brümmer
1   From the Department of Clinical Chemistry, Clinic of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany
,
Janneke Groth
1   From the Department of Clinical Chemistry, Clinic of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany
,
Raid Flayeh
1   From the Department of Clinical Chemistry, Clinic of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany
,
Christoph Wagener
1   From the Department of Clinical Chemistry, Clinic of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany
,
Roman Jung
1   From the Department of Clinical Chemistry, Clinic of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 13. September 2001

Accepted 10. Oktober 2001

Publikationsdatum:
14. Dezember 2017 (online)

 

 
  • References

  • 1 Bertina RM. Genetic approach to thrombophilia. Thromb Haemost 2001; 86: 92-103.
  • 2 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
  • 3 Dahlbäck B, Carlsson M. Factor VIII defect associated with familial thrombophilia. Thrombosis and Haemostasis 1991; 65: 658A.
  • 4 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
  • 5 Roelse JC, Koopman MM, Buller HR, ten Cate JW, Montaruli B, van Mourik JA. et al. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br J Haematol 1996; 92: 740-3.
  • 6 Bokarewa MI, Falk G, Bremme K, Blomback M, Wiman B. Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance. Eur J Clin Invest 1997; 27: 340-5.
  • 7 Hooper WC, Dilley A, Austin H, Wenger NK, Benson J, Evatt BL. et al. Absence of mutations at APC cleavage sites Arg306 in factor V and Arg336, Arg562 in factor VIII in African-Americans. Thromb Haemost 1998; 79: 236.
  • 8 Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem 1990; 265: 1484-9.
  • 9 Bertina RM, Cupers R, van Wijngaarden A. Factor IXa protects activated factor VIII against inactivation by activated protein C. Biochem Biophys Res Commun 1984; 125: 177-83.